Jack Bendheim Sells 3,520 Shares of Phibro Animal Health (NASDAQ:PAHC) Stock

Key Points

• CEO Jack Bendheim sold 3,520 shares of Phibro Animal Health at an average price of $40.18, resulting in a 5.67% decrease in his position, now totaling 58,520 shares.
• The stock is currently trading at $42.33, up 3.1%, with a market capitalization of $1.72 billion.
• Phibro Animal Health reported earnings of $0.57 per share, exceeding analysts' expectations, and has set a FY 2026 EPS guidance of $2.520-2.700.

Phibro Animal Health Corporation (NASDAQ:PAHC - Get Free Report) CEO Jack Bendheim sold 3,520 shares of Phibro Animal Health stock in a transaction dated Thursday, October 23rd. The shares were sold at an average price of $40.18, for a total value of $141,433.60. Following the completion of the transaction, the chief executive officer owned 58,520 shares in the company, valued at approximately $2,351,333.60. This represents a 5.67% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Jack Bendheim also recently made the following trade(s):

• On Wednesday, October 22nd, Jack Bendheim sold 11,859 shares of Phibro Animal Health stock. The shares were sold at an average price of $40.27, for a total value of $477,561.93.
• On Monday, October 20th, Jack Bendheim sold 16,075 shares of Phibro Animal Health stock. The stock was sold at an average price of $40.38, for a total value of $649,108.50.
• On Friday, October 17th, Jack Bendheim sold 700 shares of Phibro Animal Health stock. The stock was sold at an average price of $40.03, for a total value of $28,021.00.
• On Thursday, September 18th, Jack Bendheim sold 7,022 shares of Phibro Animal Health stock. The stock was sold at an average price of $40.26, for a total value of $282,705.72.
• On Wednesday, September 10th, Jack Bendheim sold 3,520 shares of Phibro Animal Health stock. The stock was sold at an average price of $41.29, for a total value of $145,340.80.
• On Tuesday, September 9th, Jack Bendheim sold 14,080 shares of Phibro Animal Health stock. The stock was sold at an average price of $40.33, for a total value of $567,846.40.

Phibro Animal Health Trading Up 3.1%

Shares of NASDAQ:PAHC traded up $1.28 during midday trading on Friday, hitting $42.33. 295,981 shares of the stock were exchanged, compared to its average volume of 274,171. The stock has a market capitalization of $1.72 billion, a price-to-earnings ratio of 35.87, a P/E/G ratio of 1.21 and a beta of 0.83. The company has a debt-to-equity ratio of 2.46, a quick ratio of 1.25 and a current ratio of 2.76. The business's 50-day moving average price is $37.88 and its 200 day moving average price is $29.06. Phibro Animal Health Corporation has a 12 month low of $16.16 and a 12 month high of $42.80.

Phibro Animal Health (NASDAQ:PAHC - Get Free Report) last released its quarterly earnings results on Wednesday, August 27th. The company reported $0.57 earnings per share for the quarter, topping the consensus estimate of $0.52 by $0.05. The company had revenue of $378.70 million for the quarter, compared to analysts' expectations of $362.24 million. Phibro Animal Health had a return on equity of 32.14% and a net margin of 3.73%. Phibro Animal Health has set its FY 2026 guidance at 2.520-2.700 EPS. Analysts predict that Phibro Animal Health Corporation will post 1.95 earnings per share for the current year.

Phibro Animal Health Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, September 24th. Investors of record on Wednesday, September 3rd were paid a $0.12 dividend. This represents a $0.48 dividend on an annualized basis and a dividend yield of 1.1%. The ex-dividend date of this dividend was Wednesday, September 3rd. Phibro Animal Health's payout ratio is currently 40.68%.

Hedge Funds Weigh In On Phibro Animal Health

A number of institutional investors have recently modified their holdings of the company. JPMorgan Chase & Co. raised its position in shares of Phibro Animal Health by 2.9% during the second quarter. JPMorgan Chase & Co. now owns 13,005 shares of the company's stock worth $332,000 after purchasing an additional 363 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in shares of Phibro Animal Health by 4.7% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 12,164 shares of the company's stock worth $260,000 after purchasing an additional 546 shares during the period. Prospera Financial Services Inc raised its position in shares of Phibro Animal Health by 3.6% during the second quarter. Prospera Financial Services Inc now owns 19,910 shares of the company's stock worth $508,000 after purchasing an additional 690 shares during the period. Harbor Capital Advisors Inc. raised its position in shares of Phibro Animal Health by 7.1% during the third quarter. Harbor Capital Advisors Inc. now owns 10,589 shares of the company's stock worth $428,000 after purchasing an additional 704 shares during the period. Finally, State of Alaska Department of Revenue raised its position in shares of Phibro Animal Health by 7.6% during the second quarter. State of Alaska Department of Revenue now owns 12,129 shares of the company's stock worth $309,000 after purchasing an additional 859 shares during the period. 99.34% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on PAHC shares. Weiss Ratings reaffirmed a "hold (c)" rating on shares of Phibro Animal Health in a research note on Tuesday, October 14th. Zacks Research raised Phibro Animal Health from a "hold" rating to a "strong-buy" rating in a research note on Monday, September 29th. Morgan Stanley set a $34.00 price target on Phibro Animal Health in a research note on Thursday, August 28th. Bank of America boosted their price target on Phibro Animal Health from $19.00 to $27.00 and gave the company an "underperform" rating in a research note on Friday, August 29th. Finally, JPMorgan Chase & Co. raised Phibro Animal Health from a "neutral" rating to an "overweight" rating and boosted their price target for the company from $25.00 to $35.00 in a research note on Monday, July 7th. One investment analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, four have issued a Hold rating and two have assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, Phibro Animal Health presently has a consensus rating of "Hold" and a consensus target price of $28.40.

About Phibro Animal Health

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.